Literature DB >> 25726090

Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review.

R Fliefel1, M Tröltzsch2, J Kühnisch3, M Ehrenfeld2, S Otto2.   

Abstract

The aim of this systematic review was to answer the question: What are the treatments available for bisphosphonate-related osteonecrosis of the jaws (BRONJ) and their outcomes? A literature search of PubMed, Cochrane Library, and Web of Science databases was conducted in accordance with the PRISMA statement, search phrases were ('jaw osteonecrosis' OR 'bisphosphonate-related osteonecrosis' OR 'bisphosphonate osteonecrosis') AND ('treatment' OR 'outcomes'). Ninety-seven articles published between 2003 and February 2014 were reviewed. The studies reported 4879 cases of BRONJ. The mean age of the patients was 66.5 ± 4.7 years. The male to female ratio was 1:2. The mean duration of bisphosphonate (BP) administration was 38.2 ± 15.7 months. The quality of the publications was good, with some moderate and poor. Minimally invasive surgical treatment was the treatment most used. Medical treatment was also used. Adjunctive treatments included laser, growth factors, hyperbaric oxygen and ozone. The articles provided a broad range of outcome variables to assess the treatment of BRONJ and the outcomes of each treatment. Considerable heterogeneity was found regarding study design, sample size, and treatment modalities. Clinical trials with larger samples are required to provide sufficient information for each treatment modality to predict the outcomes of each treatment.
Copyright © 2015 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BRONJ; bisphosphonates; management; outcomes; risk factors; systematic review

Mesh:

Substances:

Year:  2015        PMID: 25726090     DOI: 10.1016/j.ijom.2015.01.026

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  69 in total

Review 1.  Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Authors:  Victoria Rollason; Alexandra Laverrière; Laura C I MacDonald; Tanya Walsh; Martin R Tramèr; Nicole B Vogt-Ferrier
Journal:  Cochrane Database Syst Rev       Date:  2016-02-26

Review 2.  Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity.

Authors:  Valesca Sander Koth; Maria Antonia Figueiredo; Fernanda Gonçalves Salum; Karen Cherubini
Journal:  Dentomaxillofac Radiol       Date:  2016-05-31       Impact factor: 2.419

3.  Effects of EGF-coated titanium surfaces on adhesion and metabolism of bisphosphonate-treated human keratinocytes and gingival fibroblasts.

Authors:  Taisa Nogueira Pansani; Laís Medeiros Cardoso; Luisa Ammirabile Augusto; Isabela Massaro Ribeiro; Carlos Alberto de Souza Costa; Fernanda Gonçalves Basso
Journal:  Clin Oral Investig       Date:  2021-04-14       Impact factor: 3.573

4.  Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris).

Authors:  J G Messer; E J Castillo; A M Abraham; J M Jiron; R Israel; J F Yarrow; S Thomas; M C Reynolds; R D Wnek; M Jorgensen; N Wanionok; C Van Poznak; I Bhattacharyya; D B Kimmel; J I Aguirre
Journal:  Bone       Date:  2019-11-07       Impact factor: 4.398

5.  Osteoporotic Conditions Influence the Activity of Adipose-Derived Stem Cells.

Authors:  Jeong Seop Park; Jiyuan Piao; Gabee Park; Kyung Sang Yoo; Hyun Sook Hong
Journal:  Tissue Eng Regen Med       Date:  2020-09-18       Impact factor: 4.169

6.  Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy.

Authors:  Valesca S Koth; Maria A Figueiredo; Fernanda G Salum; Karen Cherubini
Journal:  Dentomaxillofac Radiol       Date:  2017-02-17       Impact factor: 2.419

7.  Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases.

Authors:  Yuki Matsushita; Saki Hayashida; Kota Morishita; Hiroshi Sakamoto; Tomofumi Naruse; Yuki Sakamoto; Shin-Ichi Yamada; Souichi Yanamoto; Shuichi Fujita; Tohru Ikeda; Masahiro Umeda
Journal:  Mol Clin Oncol       Date:  2015-12-07

8.  Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw.

Authors:  Saki Hayashida; Souichi Yanamoto; Shigeyuki Fujita; Takumi Hasegawa; Takahide Komori; Yuka Kojima; Hironori Miyamoto; Yasuyuki Shibuya; Nobuhiro Ueda; Tadaaki Kirita; Hirokazu Nakahara; Mitsuyo Shinohara; Eiji Kondo; Hiroshi Kurita; Masahiro Umeda
Journal:  J Bone Miner Metab       Date:  2019-08-13       Impact factor: 2.626

Review 9.  Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday.

Authors:  Jordan C Villa; Arianna Gianakos; Joseph M Lane
Journal:  HSS J       Date:  2015-12-09

10.  Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw.

Authors:  Tomoya Soma; Ryotaro Iwasaki; Yuiko Sato; Tami Kobayashi; Satoshi Nakamura; Yosuke Kaneko; Eri Ito; Hiroyuki Okada; Hisato Watanabe; Kana Miyamoto; Morio Matsumoto; Masaya Nakamura; Seiji Asoda; Hiromasa Kawana; Taneaki Nakagawa; Takeshi Miyamoto
Journal:  J Bone Miner Metab       Date:  2020-11-17       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.